Keywords: Concordia Phama, Ono Pharma, Salirasib, Panreactic, Lung, Colorectal cancer, Japan
Concordia Pharma grants Japan’s Ono Pharma rights to salirasib cancer drug
Article | 03 September 2010
Florida, USA-based Concordia Pharmaceuticals, a privately-held biotech company, has granted Japanese drugmaker Ono Pharmaceutical (TYO: 4528) exclusive rights to develop and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
